Organization | Saptalis Pharmaceuticals

Saptalis Pharmaceuticals Report issue

For profit Phase 3

Founded: Hauppage NY United States (2015)

Status: No NME R&D (2015)

Organization Overview

First Clinical Trial

2018

NCT03973775

First Marketed Drug

2015

urea

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Saptalis Pharmaceuticals | SAPTALIS PHARMACEUTICALS, LLC | SAPTALIS PHARMS

Active Ingredients

Marketed Drugs (11)

acetic acid (vosol) (2005)

cetirizine (zyrtec) (2009)

clobetasol (dermovate) (2019)

erythromycin (ilosone) (1988)

levocarnitine (carnitor) (2021)

lorazepam (ativan) (2009)

memantine (namenda) (2020)

metformin (glucophage) (2020)

potassium chloride (klor-con) (2021)

triamcinolone (kenalog) (2006)

urea (1961)

Drugs in Phase 3 Trials (1)

permethrin (nix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Scabies (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 1
# of Trial APIs: 1